Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 12/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224874 | 0.87 | HDAC1 (0.41) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2221319 | 0.87 | HDAC4 (0.53) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2351016 | 0.83 | GAA (0.43) | HDAC4HDAC7HDAC5HDAC6GAA | |
| SCHEMBL2354587 | 0.82 | HDAC4 (0.45) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2222262 | 0.81 | HDAC4 (0.36) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2222463 | 0.79 | TSHR (0.43) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL14243906 | 0.79 | HDAC1 (0.41) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2274396 | 0.79 | HDAC8 (0.41) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2221985 | 0.78 | HDAC4 (0.44) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL14297309 | 0.78 | HPGD (0.39) | HDAC4HDAC1HDAC8HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | claimed |
| WO-2013009812-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| EP-2523560-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HDAC4 2086/4885HDAC1 1086/4885HDAC8 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.